Annual EBITDA:
$656.54M+$204.59M(+45.27%)Summary
- As of today, HALO annual EBITDA is $656.54 million, with the most recent change of +$204.59 million (+45.27%) on December 31, 2024.
- During the last 3 years, HALO annual EBITDA has risen by +$397.50 million (+153.45%).
- HALO annual EBITDA is now at all-time high.
Performance
HALO EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Quarterly EBITDA:
$229.83M+$61.03M(+36.16%)Summary
- As of today, HALO quarterly EBITDA is $229.83 million, with the most recent change of +$61.03 million (+36.16%) on June 30, 2025.
- Over the past year, HALO quarterly EBITDA has increased by +$87.24 million (+61.18%).
- HALO quarterly EBITDA is now at all-time high.
Performance
HALO Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM EBITDA:
$791.84M+$87.24M(+12.38%)Summary
- As of today, HALO TTM EBITDA is $791.84 million, with the most recent change of +$87.24 million (+12.38%) on June 30, 2025.
- Over the past year, HALO TTM EBITDA has increased by +$272.07 million (+52.34%).
- HALO TTM EBITDA is now at all-time high.
Performance
HALO TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
HALO EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1Y1 Year | +45.3% | +61.2% | +52.3% |
| 3Y3 Years | +153.4% | +403.4% | +208.3% |
| 5Y5 Years | +1260.9% | +625.0% | +1691.8% |
HALO EBITDA Highs & Lows
| PeriodPeriod | Annual vs HighAnnual vs High | Annual vs LowAnnual vs Low | Quarter. vs HighQuarter. vs High | Quarter. vs LowQuarter. vs Low | TTM vs HighTTM vs High | TTM vs LowTTM vs Low | |
|---|---|---|---|---|---|---|---|
| 3Y | 3-Year | at high | +153.4% | at high | +197.6% | at high | +172.4% |
| 5Y | 5-Year | at high | +1260.9% | at high | +646.5% | at high | +1691.8% |
| All-Time | All-Time | at high | +926.1% | at high | +874.2% | at high | +938.5% |
HALO EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Jun 2025 | - | $229.83M(+36.2%) | $791.84M(+12.4%) |
| Mar 2025 | - | $168.80M(-16.9%) | $704.60M(+7.3%) |
| Dec 2024 | $656.54M(+45.3%) | $203.17M(+6.9%) | $656.54M(+13.1%) |
| Sep 2024 | - | $190.03M(+33.3%) | $580.46M(+11.7%) |
| Jun 2024 | - | $142.60M(+18.1%) | $519.77M(+4.9%) |
| Mar 2024 | - | $120.74M(-5.0%) | $495.45M(+9.6%) |
| Dec 2023 | $451.95M(+43.2%) | $127.09M(-1.7%) | $451.95M(+11.0%) |
| Sep 2023 | - | $129.34M(+9.4%) | $407.33M(+4.9%) |
| Jun 2023 | - | $118.28M(+53.1%) | $388.42M(+23.0%) |
| Mar 2023 | - | $77.24M(-6.3%) | $315.80M(+0.1%) |
| Dec 2022 | $315.51M(+21.8%) | $82.47M(-25.3%) | $315.51M(+8.5%) |
| Sep 2022 | - | $110.42M(+141.8%) | $290.67M(+13.2%) |
| Jun 2022 | - | $45.66M(-40.7%) | $256.86M(-15.8%) |
| Mar 2022 | - | $76.95M(+33.5%) | $305.20M(+17.8%) |
| Dec 2021 | $259.04M(+69.3%) | $57.64M(-24.8%) | $259.04M(-7.6%) |
| Sep 2021 | - | $76.61M(-18.5%) | $280.49M(+14.0%) |
| Jun 2021 | - | $94.00M(+205.3%) | $245.94M(+33.9%) |
| Mar 2021 | - | $30.79M(-61.1%) | $183.64M(+20.1%) |
| Dec 2020 | $152.96M(+370.5%) | $79.08M(+88.0%) | $152.96M(+246.1%) |
| Sep 2020 | - | $42.06M(+32.7%) | $44.19M(+323.3%) |
| Jun 2020 | - | $31.70M(>+9900.0%) | -$19.79M(+68.3%) |
| Mar 2020 | - | $113.00K(+100.4%) | -$62.46M(-10.4%) |
| Dec 2019 | -$56.56M(+4.7%) | -$29.69M(-35.4%) | -$56.56M(-132.4%) |
| Sep 2019 | - | -$21.92M(-100.0%) | -$24.33M(+4.1%) |
| Jun 2019 | - | -$10.96M(-282.3%) | -$25.36M(+20.4%) |
| Mar 2019 | - | $6.01M(+137.1%) | -$31.87M(+46.3%) |
| Dec 2018 | -$59.36M(-169.2%) | $2.54M(+111.0%) | -$59.36M(-190.5%) |
| Sep 2018 | - | -$22.95M(-31.4%) | $65.60M(-33.0%) |
| Jun 2018 | - | -$17.47M(+18.7%) | $97.92M(+7.7%) |
| Mar 2018 | - | -$21.48M(-116.8%) | $90.91M(+6.0%) |
| Dec 2017 | $85.75M(+207.9%) | $127.50M(+1261.8%) | $85.75M(+235.4%) |
| Sep 2017 | - | $9.36M(+138.3%) | -$63.31M(+33.0%) |
| Jun 2017 | - | -$24.47M(+8.1%) | -$94.43M(-4.2%) |
| Mar 2017 | - | -$26.64M(-23.5%) | -$90.66M(-14.1%) |
| Dec 2016 | -$79.47M(-213.5%) | -$21.57M(+0.9%) | -$79.47M(-53.3%) |
| Sep 2016 | - | -$21.75M(-5.1%) | -$51.83M(+1.9%) |
| Jun 2016 | - | -$20.70M(-34.0%) | -$52.83M(-92.7%) |
| Mar 2016 | - | -$15.45M(-354.2%) | -$27.42M(-8.1%) |
| Dec 2015 | -$25.35M(+58.5%) | $6.08M(+126.7%) | -$25.35M(+27.3%) |
| Sep 2015 | - | -$22.76M(-582.9%) | -$34.87M(-14.1%) |
| Jun 2015 | - | $4.71M(+135.2%) | -$30.55M(+38.5%) |
| Mar 2015 | - | -$13.39M(-289.4%) | -$49.65M(+18.7%) |
| Dec 2014 | -$61.03M(+22.7%) | -$3.44M(+81.4%) | -$61.03M(+22.3%) |
| Sep 2014 | - | -$18.44M(-28.2%) | -$78.52M(-0.4%) |
| Jun 2014 | - | -$14.38M(+42.0%) | -$78.22M(+8.6%) |
| Mar 2014 | - | -$24.77M(-18.4%) | -$85.61M(-8.4%) |
| Dec 2013 | -$78.98M | -$20.93M(-15.4%) | -$78.98M(-27.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2013 | - | -$18.14M(+16.7%) | -$62.17M(+2.5%) |
| Jun 2013 | - | -$21.77M(-20.0%) | -$63.75M(-14.4%) |
| Mar 2013 | - | -$18.14M(-340.1%) | -$55.74M(-6.2%) |
| Dec 2012 | -$52.47M(-181.0%) | -$4.12M(+79.1%) | -$52.47M(+21.1%) |
| Sep 2012 | - | -$19.72M(-43.4%) | -$66.46M(-60.7%) |
| Jun 2012 | - | -$13.75M(+7.6%) | -$41.35M(-70.7%) |
| Mar 2012 | - | -$14.88M(+17.8%) | -$24.22M(-29.7%) |
| Dec 2011 | -$18.67M(+64.6%) | -$18.11M(-436.0%) | -$18.67M(-3.2%) |
| Sep 2011 | - | $5.39M(+59.4%) | -$18.10M(+49.1%) |
| Jun 2011 | - | $3.38M(+136.2%) | -$35.56M(+29.9%) |
| Mar 2011 | - | -$9.33M(+46.8%) | -$50.71M(+3.9%) |
| Dec 2010 | -$52.75M(+7.5%) | -$17.54M(-45.3%) | -$52.75M(-11.1%) |
| Sep 2010 | - | -$12.07M(-2.6%) | -$47.49M(+3.1%) |
| Jun 2010 | - | -$11.76M(-3.4%) | -$48.99M(+9.2%) |
| Mar 2010 | - | -$11.38M(+7.4%) | -$53.96M(+5.4%) |
| Dec 2009 | -$57.01M(-15.4%) | -$12.28M(+9.5%) | -$57.01M(+7.2%) |
| Sep 2009 | - | -$13.57M(+18.9%) | -$61.47M(-4.5%) |
| Jun 2009 | - | -$16.73M(-16.0%) | -$58.82M(-10.5%) |
| Mar 2009 | - | -$14.43M(+13.8%) | -$53.21M(-7.7%) |
| Dec 2008 | -$49.39M(-79.1%) | -$16.74M(-53.3%) | -$49.39M(-16.6%) |
| Sep 2008 | - | -$10.92M(+1.9%) | -$42.36M(-7.0%) |
| Jun 2008 | - | -$11.13M(-4.9%) | -$39.60M(-15.8%) |
| Mar 2008 | - | -$10.61M(-9.2%) | -$34.19M(-24.0%) |
| Dec 2007 | -$27.57M(-79.8%) | -$9.71M(-19.1%) | -$27.57M(-22.8%) |
| Sep 2007 | - | -$8.16M(-42.9%) | -$22.46M(-24.3%) |
| Jun 2007 | - | -$5.71M(-43.0%) | -$18.06M(-15.0%) |
| Mar 2007 | - | -$3.99M(+13.1%) | -$15.71M(-2.4%) |
| Dec 2006 | -$15.34M(-14.9%) | -$4.60M(-22.2%) | -$15.34M(-7.5%) |
| Sep 2006 | - | -$3.76M(-12.1%) | -$14.27M(-0.3%) |
| Jun 2006 | - | -$3.36M(+7.2%) | -$14.23M(-3.4%) |
| Mar 2006 | - | -$3.62M(-2.6%) | -$13.75M(-3.0%) |
| Dec 2005 | -$13.36M(-49.0%) | -$3.53M(+5.2%) | -$13.36M(-8.4%) |
| Sep 2005 | - | -$3.72M(-29.0%) | -$12.32M(-4.2%) |
| Jun 2005 | - | -$2.88M(+10.4%) | -$11.82M(-7.5%) |
| Mar 2005 | - | -$3.22M(-29.4%) | -$11.00M(-22.7%) |
| Dec 2004 | -$8.96M(>-9900.0%) | -$2.49M(+23.0%) | -$8.96M(-64.7%) |
| Sep 2004 | - | -$3.23M(-56.9%) | -$5.44M(-109.3%) |
| Jun 2004 | - | -$2.06M(-73.6%) | -$2.60M(-190.1%) |
| Mar 2004 | - | -$1.19M(-214.9%) | -$896.50K(-1721.2%) |
| Dec 2003 | $0.00(0.0%) | $1.03M(+366.3%) | $55.30K(+105.8%) |
| Sep 2003 | - | -$387.70K(-9.1%) | -$958.70K(-64.3%) |
| Jun 2003 | - | -$355.20K(-51.6%) | -$583.60K(-136.6%) |
| Mar 2003 | - | -$234.30K(-1366.5%) | -$246.70K(>-9900.0%) |
| Dec 2002 | $0.00(+100.0%) | $18.50K(+246.8%) | $0.00(+100.0%) |
| Sep 2002 | - | -$12.60K(+31.1%) | -$18.50K(-213.6%) |
| Jun 2002 | - | -$18.30K(-247.6%) | -$5900.00(-147.6%) |
| Mar 2002 | - | $12.40K | $12.40K |
| Dec 2001 | -$39.70K | - | - |
FAQ
- What is Halozyme Therapeutics, Inc. annual EBITDA?
- What is the all-time high annual EBITDA for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. annual EBITDA year-on-year change?
- What is Halozyme Therapeutics, Inc. quarterly EBITDA?
- What is the all-time high quarterly EBITDA for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. quarterly EBITDA year-on-year change?
- What is Halozyme Therapeutics, Inc. TTM EBITDA?
- What is the all-time high TTM EBITDA for Halozyme Therapeutics, Inc.?
- What is Halozyme Therapeutics, Inc. TTM EBITDA year-on-year change?
What is Halozyme Therapeutics, Inc. annual EBITDA?
The current annual EBITDA of HALO is $656.54M
What is the all-time high annual EBITDA for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high annual EBITDA is $656.54M
What is Halozyme Therapeutics, Inc. annual EBITDA year-on-year change?
Over the past year, HALO annual EBITDA has changed by +$204.59M (+45.27%)
What is Halozyme Therapeutics, Inc. quarterly EBITDA?
The current quarterly EBITDA of HALO is $229.83M
What is the all-time high quarterly EBITDA for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high quarterly EBITDA is $229.83M
What is Halozyme Therapeutics, Inc. quarterly EBITDA year-on-year change?
Over the past year, HALO quarterly EBITDA has changed by +$87.24M (+61.18%)
What is Halozyme Therapeutics, Inc. TTM EBITDA?
The current TTM EBITDA of HALO is $791.84M
What is the all-time high TTM EBITDA for Halozyme Therapeutics, Inc.?
Halozyme Therapeutics, Inc. all-time high TTM EBITDA is $791.84M
What is Halozyme Therapeutics, Inc. TTM EBITDA year-on-year change?
Over the past year, HALO TTM EBITDA has changed by +$272.07M (+52.34%)